Methylphenidate Hydrochloride Solution
Loading...Methylphenidate Hydrochloride Solution Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
BACTROBAN nasal ointment is indicated for the eradication of nasal colonization with methicillin‑resistant Staphylococcus aureus (MRSA) in adult and pediatric patients (aged 12 years and older) and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of MRSA infection during institutional outbreaks of infections with this microorganism.
- •
- There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with Staphylococcus aureus ( S. aureus).
- •
- There are insufficient data at this time to recommend use of BACTROBAN nasal ointment for general prophylaxis of any infection in any patient population.
History
There is currently no drug history available for this drug.
Other Information
BACTROBAN (mupirocin calcium) nasal ointment, 2% contains the dihydrate crystalline calcium hemi‑salt of the antibacterial drug, mupirocin. Chemically, it is (αE,2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-methyl-2H-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dihydrate.
The molecular formula of mupirocin calcium is (C26H43O9)2Ca•2H2O, and the molecular weight is 1075.3. The molecular weight of mupirocin free acid is 500.6. The structural formula of mupirocin calcium is:
BACTROBAN nasal ointmentis a white to off‑white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2% mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN® 649).
Sources
Methylphenidate Hydrochloride Solution Manufacturers
-
Tris Pharma, Inc.
![Methylphenidate Hydrochloride Solution [Tris Pharma, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Methylphenidate Hydrochloride Solution | Glaxosmithkline Llc
• For Intranasal Use Only. • Apply approximately one-half of the ointment from the single-use tube into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days. • After application, close the nostrils by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares. • Do not apply BACTROBAN nasal ointment concurrently with any other intranasal products [see Clinical Pharmacology (12.3)]. • The single-use 1-gram tube will deliver a total of approximately 0.5 grams of the ointment (approximately 0.25 grams per nostril). • Discard the tube after usage. Do not re-use. -
Breckenridge Pharmaceutical, Inc.
Methylphenidate Hydrochloride Solution | Breckenridge Pharmaceutical, Inc.
Dosage should be individualized according to the needs and responses of the patient.
AdultsAdminister in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may require 40 to 60 mg daily. In others, 10 to 15 mg daily will be adequate. Patients who are unable to sleep if medication is taken late in the day should take the last dose before 6 p.m.
Children (6 years and over)Methylphenidate hydrochloride oral solution should be initiated in small doses, with gradual weekly increments. Daily dosage above 60 mg is not recommended.
If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.
Start with 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.
If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage, or, if necessary, discontinue the drug.
Methylphenidate hydrochloride oral solution should be periodically discontinued to assess the child's condition. Improvement may be sustained when the drug is either temporarily or permanently discontinued.
Drug treatment should not and need not be indefinite and usually may be discontinued after puberty.
-
Caraco Pharmaceutical Laboratories, Ltd.
Methylphenidate Hydrochloride Solution | Caraco Pharmaceutical Laboratories, Ltd.
Dosage should be individualized according to the needs and responses of the patient.
AdultsAdminister in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may require 40 to 60 mg daily. In others, 10 to 15 mg daily will be adequate. Patients who are unable to sleep if medication is taken late in the day should take the last dose before 6 p.m.
Children (6 years and over)Methylphenidate Hydrochloride Oral Solution should be initiated in small doses, with gradual weekly increments. Daily dosage above 60 mg is not recommended.
If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.
Start with 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.
If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage, or, if necessary, discontinue the drug.
Methylphenidate Hydrochloride Oral Solution should be periodically discontinued to assess the child’s condition. Improvement may be sustained when the drug is either temporarily or permanently discontinued.
Drug treatment should not and need not be indefinite and usually may be discontinued after puberty.
![Methylphenidate Hydrochloride Solution [Breckenridge Pharmaceutical, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=533fc1a6-b4cf-4d73-9d41-b4fe9fe5c8af&name=methylphenidate-02.jpg)
![Methylphenidate Hydrochloride Solution [Caraco Pharmaceutical Laboratories, Ltd.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=785e47e1-3d4f-4bdd-96f8-cecb51313dd7&name=Methylphenidate_10mg5mL.jpg)
Login To Your Free Account